Abstract
Loss of nigral dopamine neurons in Parkinson's disease induces abnormal activation of glutamate systems in the basal ganglia. The purpose of this study was to assess these changes in the lentiform nucleus using MRS with optimized glutamate sensitivity (TE-averaged method). Ten patients with Parkinson's disease and 10 healthy controls were examined. Compared with healthy controls, no significant differences in glutamate were measured in patients, but a trend to lower total creatine was observed.
MeSH terms
-
Antiparkinson Agents / therapeutic use
-
Aspartic Acid / analogs & derivatives
-
Aspartic Acid / metabolism
-
Corpus Striatum / metabolism*
-
Creatine / metabolism
-
Glutamic Acid / metabolism*
-
Glutamine / metabolism
-
Humans
-
Levodopa / therapeutic use
-
Magnetic Resonance Spectroscopy
-
Parkinson Disease / diagnosis
-
Parkinson Disease / drug therapy
-
Parkinson Disease / metabolism*
-
Reference Values
-
gamma-Aminobutyric Acid / metabolism
Substances
-
Antiparkinson Agents
-
Glutamine
-
Aspartic Acid
-
Glutamic Acid
-
Levodopa
-
gamma-Aminobutyric Acid
-
N-acetylaspartate
-
Creatine